InvestorsHub Logo

centsability4me

08/19/22 9:25 PM

#52887 RE: BigBadWolf #52885

“On August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.”

https://forum.therapeuticsolutionsint.com/viewtopic.php?t=333

Nothing2c

08/19/22 10:10 PM

#52888 RE: BigBadWolf #52885

Quick review shows they are cash poor —- like many small biotech companies. They might be forced to do another equity offering to finance the testing.

Nice to see revenue go up 300% versus 2021.